Metabolon Delivers Large-Scale Metabolomics Dataset to Genomics England’s 100,000 Genomes Project to Advance Rare Disease Research
Dataset from more than 7,500 participants expands multiomic analysis in rare disease research by combining metabolomics with genomic and clinical data MORRISVILLE, N.C., June 24, 2026 /PRNewswire/ -- Metabolon, Inc., the global leader in metabolomics solutions advancing life science research, diagnostics, therapeutics, and precision medicine, today announced the successful completion and delivery...
Frost & Sullivan: Aileen.ai Receives the 2026 North American Transformational Innovation Leadership Recognition for Advancing Relationship-Based AI-Enabled Senior Care
The company's innovative AI health companion enhances continuity of care through scalable, relationship-based support for older adults SAN ANTONIO, June 24, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Aileen.ai has been honored with the 2026 North American Transformational Innovation Leadership Recognition in the AI health companion for seniors industry for its outstanding achievements in product...
HKeyBio Launches NHP Fast-Tox Program for Accelerating Non-GLP NHP Safety Risk Screening
The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics and immunomodulatory drug programs BOSTON and SUZHOU, China, June 24, 2026 /PRNewswire/ -- HKeyBio, a preclinical CRO focused on autoimmune and allergic disease research, today announced the launch of its NHP Fast-Tox Program, an early toxicology screening solution designed to help...
IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
IMU's AI platform unlocks unprecedented immune insights for cancer and other diseases, measuring 100M+ data points from a single blood sample, analyzed in real time. Waters Biosciences' technologies, including BD FACSDiscover™ and BD Rhapsody™ Instruments, will be used with IMU's AI analytics in research to deliver deeper, population-level disease insights....
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
VALBY, Denmark, June 24, 2026 /PRNewswire/ -- H. Lundbeck A/S (Lundbeck) today announced that Tarek Samad has been appointed Executive Vice President and Head of Research & Development (R&D) and will join the Executive Leadership Team (ELT) effective 1 September 2026. Tarek Samad succeeds Johan Luthman, who has informed the Board of Directors and ELT of his decision...
Ping An Good Doctor CEO He Mingke Speaks At 2026 Summer Davos: China Is Entering Its Own “Longevity Era”
HONG KONG and SHANGHAI, June 24, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or the "Group"; HKEX: 2318/82318; SSE: 601318) attended the World Economic Forum's 17th Annual Meeting of the New Champions, also known as Summer Davos 2026, convened at the Dalian International Conference Center on 23 June, 2026. This year's forum...
Yidu Tech’s Gong Yingying at Summer Davos: Building Evidence Infrastructure to Expand Access to Innovative Medicines
DALIAN, China, June 24, 2026 /PRNewswire/ -- On June 23, at the 17th Annual Meeting of the New Champions (Summer Davos 2026) hosted by the World Economic Forum in Dalian, Gong Yingying, Founder and Chairlady of Yidu Tech, participated in the panel discussion "Faster Drugs, Better Access?". She shared her perspectives on the structural transformation of global pharmaceutical R&D...
World’s First Solid Tumor CAR-T Approved: Jiahui International Cancer Center Provides Access for Patients Worldwide
SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment of a solid tumor, marking a historic milestone in cancer care and opening new possibilities for patients from around the world. Approved by China's National Medical Products Administration (NMPA), Satri-cel...
Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart Eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, psychological well-being, and workplace productivity Late breaker bocunebart presentation will provide further insight...
Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules
SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, which were approved by the National Medical Products...
